Month: June 2026

Introduction and Objective: Older adults benefit from continuous glucose monitoring (CGM) use, but CGM initiation and sustained use often require intensive educator support, and time requirements are poorly characterized. We quantified educator time and support needs during the REST study.Methods: REST is a prospective 12-month study conducted in older adults (≥65 years) with insulin-treated diabetes, […]

Introduction and Objective: The iCan CGM system is equipped with 3rd generation sensor technology and based on a different enzyme (GDH-FAD) than other FDA approved CGM systems in US. This 15d factory calibrated sensor is available in many regulated markets worldwide and was evaluated in a multi-center study for iCGM compliance in a pediatric sample […]

Introduction and Objective: Type 2 diabetes (T2D) is associated with elevated cancer risk, yet whether heterogeneity in T2D identifies individuals at particularly high or low risk relative to individuals without diabetes remains unclear. We evaluated site-specific cancer risk across T2D subtypes compared with adults without diabetes.Methods: We analyzed retrospective electronic health records from Epic Cosmos […]

Introduction and Objective: Despite recent improvements in generating functional human insulin-producing β cells, stem cell-derived beta-like cells (sBC) still develop and function less efficiently than bona fide β cells from cadaveric islets. Therefore, we sought to identify key factors affecting efficient sBC generation during differentiation, with a focus on reducing time for sBC generation while […]

Introduction and Objective: Use of dual glucagon-like-peptide-1/glucose-dependent insulinotropic polypeptide receptor-agonists is increasing in overweight/obese (OW/OB) individuals with T1D. Their effects on DR in individuals with T1D are unknown.Methods: Retrospective chart review of OW/OB individuals with T1D at the Barbara Davis Center for Diabetes. Individuals who used tirzepatide for 12 ± 2 months (cases) were matched […]

Introduction and Objective: Despite cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i), treatment persistence is suboptimal in routine clinical practice. We investigated whether longer treatment durations offer greater cardiovascular benefits.Methods: We used nationwide healthcare data of South Korea (2012-2023) to emulate a target trial comparing following treatment strategies: treated with SGLT2i for <1 year, 1-2 […]

Introduction and Objective: T2DM is often driven by obesity, which leads to impaired glucose homeostasis and β-cell dysfunction. While oral small-molecule GLP-1RAs, such as orforglipron, promote weight reduction, dose-dependent gastrointestinal adverse effects can limit adherence. Dorzagliatin, a first-in-class glucokinase activator, enhances glucose sensing and early-phase insulin secretion. We evaluated whether combining these two oral agents […]

Introduction and Objective: Transitioning to college increases the risk for hypoglycemia due to irregular schedules, alcohol use, and unpredictable access to food or glucose, highlighting the need for campus-based training to improve hypoglycemia-related safety. This study evaluated the effectiveness of HYPO-VR for on-campus hypoglycemia education.Methods: We conducted a two-arm pilot educational trial with undergraduate students. […]

Introduction and Objective: The rising prevalence of obesity and related comorbidities highlights the need for safe, effective, and durable therapies. We evaluated PTT-A, a novel long-acting tetra-agonist targeting GLP-1, GIP, amylin, and calcitonin receptors, in diet-induced obese (DIO) rats and compared its efficacy with tirzepatide and CagriSema.Methods: DIO rats received PTT-A (10 or 30 nmol/kg), […]